Telomir Pharmaceuticals, Inc. (TELO): auditor change — Telomir Pharmaceuticals replaces auditor Cherry Bekaert with Salberg & Company after material weakness disclosure

Telomir Pharmaceuticals, Inc.

Cherry Bekaert LLP resigned as independent auditor effective Dec 16, 2024; no disagreements on accounting principles.
Auditor previously identified material weaknesses in internal control over financial reporting as of Dec 31, 2023 and 2022.
Company engaged Salberg & Company P.A. as new independent registered public accountant on Dec 18, 2024.
Prior audit reports (2022, 2023) were unqualified except for a going concern explanatory paragraph.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Telomir Pharmaceuticals, Inc. engaged Salberg & Company P.A. as its auditor.

Action: engagement
Auditor: Salberg & Company P.A.

Exact text from the filing

On December 18 th , 2024, the Company engaged Salberg & Company P.A. (“Salberg”) as its new independent registered public accountant for the fiscal year ending December 31, 2024.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Cherry Bekaert LLP resigned as auditor of Telomir Pharmaceuticals, Inc..

Action: resignation
Auditor: Cherry Bekaert LLP

Exact text from the filing

By letter dated December 16, 2024, Cherry Bekaert LLP (“Cherry Bekaert”) notified the Audit Committee of the Board of Directors (the “Audit Committee”) of Telomir Pharmaceuticals, Inc’s (the “Company”) of its resignation as the Company’s independent registered public accounting firm.

View on SEC.gov

21 auditor changes filed in the last 30 days. Browse all auditor changes →

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-051090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.